US Archives - Page 97 of 201 - European Medical Journal

Is Faster Cancer Treatment Finally Within Reach? Understanding Subcutaneous Immunotherapy

Subcutaneous (SC) delivery of immunotherapies for solid tumors has emerged as a potentially transformative approach to cancer treatment, promising comparable clinical efficacy to intravenous (IV) therapies while significantly reducing treatment time and burden on healthcare systems.

Real-World Trial Validates AI for EGFR Mutation Testing in Lung Cancer

An artificial intelligence tool trained on digital pathology slides has demonstrated clinical-grade accuracy for detecting EGFR mutations in lung adenocarcinoma and significantly reduced reliance on molecular testing, according to results from a large-scale real-world deployment study.

Artificial Sweetener Alters Vascular Function in the Brain

The non-nutritive sweetener erythritol, commonly found in sugar-free beverages, may impair brain microvascular endothelial cell function by increasing oxidative stress and disrupting nitric oxide (NO) signaling, according to new in vitro findings.

Updates in HR+ Advanced Breast Cancer

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized endocrine therapies…

Enhancing Cancer Care Through Vaccines

Patients with cancer often have a compromised immune system, which places them at an increased risk of infection that can extend beyond…

Advances in HER2-Mutant NSCLC

Mutations in HER2, also known as ERBB2, represent a distinct molecular subset of NSCLC, occurring in approximately 2–4% of cases, and are…

Targeting DLL3 in Rare Neuroendocrine Carcinoma

EpNECs are considered rare and are often associated with a poor prognosis, with up to 85% of patients presenting with advanced…

The Two Faces of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage, when most patients have underlying cirrhosis. Prognosis is…

AMJ Oncology 2.1 2025

Explore the latest issue of AMJ Oncology, featuring expert insights from American Society of Clinical Oncology (ASCO) 2025, new research…

Neoadjuvant Therapy in TNBC: Current Landscape and Emerging Therapies

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, characterized by the…